Telix Pharmaceuticals
$15.16Change from previous close: −2.88%Absolute change: −$0.45
Valuation
Data as of October 3, 2026
Valuation multiples
- Market cap
- $5.14B
- Enterprise value
- $5.48B
- P/E (trailing 12 months)
- 108.3
- Forward P/E
- -823.5
- Price/book
- 7.63
- Price/sales
- 5.77
- EV/EBITDA
- 78.5
- EV/revenue
- 6.15
Profitability and growth
- Gross margin
- 47.6%
- Operating margin
- 9.7%
- Net margin
- 3.8%
- ROE
- 7.4%
- ROA
- 2.7%
- Revenue growth (year over year)
- 22.3%
Financial health
- Total cash
- $251.91M
- Total debt
- $579.86M
- Debt/equity
- 1.19
- Current ratio
- 2.01
- Quick ratio
- 1.74
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $24.14
- Median price target
- $22.00
- High price target
- $32.00
- Low price target
- $19.00
- Analysts with a price target
- 11
- Consensus
- Strong buy
- Forward EPS
- -$0.02
- EPS estimate, current year
- $0.07
Shares and trading
- Beta
- 0.60
- Average volume
- 1.94M
- Shares outstanding
- 338.78M
- Float
- 273.61M
- Institutional ownership
- 34.2%
- Insider ownership
- 15.8%